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Abstract 
Background: Vulva intraepithelial neoplasia (VIN) is a noninvasive potential precursor of squamous cell 
carcinoma of the vulva. VIN is more prevalent in HIV-positive than HIV-negative women and if not identified 
and treated early, there is a high risk of progression to invasive cancer. Despite a large number of HIV-positive 
women getting care from Immunesuppression (ISS) clinic at Mbarara Regional Referral Hospital (MRRH), the 
local burden of VIN remains unknown in this group. Objective: To determine the prevalence and factors 
associated with vulva intraepithelial neoplasia (VIN) among HIV-positive women attending HIV care clinic at 
Mbarara Regional Referral Hospital (MRRH). Methods: This cross sectional study consisted of 225 HIV-
positive women who attended the HIV care clinic at MRRH in a period of three months. Simple random 
sampling was used in the recruitment of study participants until the sample size was achieved. All participants 
underwent vulvoscopy. Any lesion detected was biopsied. Demographic and medical data were collected. The 
dependent variable was histologically confirmed VIN. Logistic regression analysis to assess association of 
factors with VIN was done. Results were presented in charts, graphs and tables.  Results: Two hundred and 
twenty five HIV-positive women were enrolled. Their median age was 33 years.  14 (6.22%) had VIN; of these, 
9 had VIN-1, 4 had VIN-2 and 1 had VIN-3. All the study participants with VIN had Human papilloma virus 
(HPV) infection and were on antiretroviral therapy (ART). The symptoms of VIN included vulvar itching (43%), 
vulvar burning sensation (29%), and superficial dyspareunia (14%). Age, multiple sexual partners, age of sexual 
debut, menarche and genital warts were not significantly associated with VIN Conclusion: The prevalence of 
VIN among HIV-positive women attending HIV care clinic at MRRH is low. All participants with VIN had the 
following in common, HPV infection; vulva itching, vulva burning sensation and superficial dyspareunia. 
Recommendations:  Since all cases of VIN had HPV infection we recommend that HPV vaccination should be 
included in HIV care to prevent VIN and consequently vulva cancer. We also recommend that all women with 
vulva itching, vulva burning and superficial dyspareunia should be screened for VIN.  
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1. Introduction 
Vulva intraepithelial neoplasia is a noninvasive potential precursor of squamous cell carcinoma of the vulva 
(Hart WR et al., 2001). It has been found to be more frequent in patients with a younger age group (20-40 years) 
compared to vulva cancer; the average age being as low as 33 years (Dutta D.C. et al.,2012). The incidence of 
vulva intraepithelial neoplasia (VIN) is increasing, with 60–75% occurring in young women (Joura EA et al., 
2000, Judson PL et al., 2006, Jones RW et al., 2005). The risk of progression from VIN to invasive cancer is 3 to 
9 percent (Jones RW et al., 2005, van Seters M et al., 2005). The factors that contribute to the etiology of vulva 
carcinoma include vulva dystrophy (lichen sclerosus), a history of genital HPV-infection, and history of cervical 
neoplasia, advanced age, smoking and a compromised immunity (e.g. HIV). For the development of a vulvar 
carcinoma, more than one of the above mentioned factors has to be present (Ansink AC et al., 1993). High-risk 
human papillomavirus (HRHPV) is an established cause of a significant proportion of vulva intraepithelial 
neoplasia (VIN) (Koutsky L et al., 1997; van der Avoort IA et al., 2006; Skapa P et al., 2007) and this has been 
found to be more frequent in immune-compromised women. 
Women with human immunodeficiency virus (HIV) infection are at an increased risk of vulvar neoplasia 
(Maiman M et al., 1990; Clark RA et al., 1993; Korn AP et al., 1996). The incidence and severity of vulvar 
premalignant and malignant disease appeared to correlate with worsening immunosuppression (Spitzer M et al., 
1999; Robinson WR et al., 1997). Cervical intraepithelial neoplasia (CIN) has also been found to be high among 
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HIV-positive women (Ellerbrock TV et al., 2000). Despite standard therapy, HIV-infected women with vulva 
neoplasia have higher rates of persistence and recurrence than the general population (Maiman M et al., 1997; 
Dedes KJ et al., 2008).  
HIV-positive women are five times more likely than HIV-negative women to develop lower genital tract 
neoplasia (Ferenczy A et al., 2003) and they have a 16-fold increase in lower genital tract lesions (excluding the 
cervix) than HIV-negative women (Conley LJ et al., 2002).The prevalence of VIN among HIV-seropositive 
women ranges from 5.6 to 57% (Kappler et al., 2011; Byrne MA et al., 1989; Chiasson MA et al., 1997; Korn 
AP et al., 1998; and OlamideDosekun et al., 2013).  With the advent of HAART, the life expectancy of these 
women is increasing with an increased risk of developing high risk lesion which may progress to cancer 
(Francheschi S and Jaffe H, 2007). 
2. Materials and Methods 
2.1 Participants 
This cross-sectional study consisted of 225HIV-positive women aged 18 years and above registered and 
attending the Immune Suppression Syndrome (ISS) clinic at Mbarara Regional Referral Hospital (MRRH) 
between January and March 2015. Ethics approval was obtained from both the faculty review ethical committee 
(FREC) and institutional research ethics committee (REC) of Mbarara University of Science and Technology. 
2.2 Recruitment 
 
Eight (8) out of every first 20 HIV-positive womenwho registered each day in ISS clinic were selected by simple 
random sampling and recruited in the study. 
HIV-positive women were included in the study if they were aged 18 years and above, registered and attending 
ISS clinic at MRRH, and consented to participate in the study.Those whohadknownhistologically confirmed or 
on treatment for vulvar cancer were excluded from the study. All participants were examinedbythe principle 
investigator under supervision by two senior gynecologists with experience in colposcopy. A pre-tested 
standardized questionnaire to capture information including social demographic and medical characteristics was 
administered in the language the participant was conversant with by the principal investigator/research assistant 
to the study participant. Vulvar screening was done in a procedural room with patient on examination bed in 
lithotomy position. A thorough inspection of the vulvar was done to reveal fields of redness, leukoplakia, 
pigmentations, ulcerations, atrophy, genital warts and invasive cancer. A freshly prepared 5% acetic acid 
solution was applied on the vulva for 3-5 minutes to allow vulvar lesions to show. The colposcope was then used 
to visualize and localize the vulvar lesions; and any abnormalities (acetowhite changes, raised lesions, 
discolorations) were biopsied after infiltration with a local anesthetic (1 % Lidocainewithout epinephrine). The 
biopsy samples were put in 10% formalin in different containers, sealed, well labeled with patient particulars and 
taken to the histo-pathologist at the end of the day by the principal investigator. Results were picked after one 
week and given to the participants. Women with vulvar intraepithelial neoplasia were managed as per the 
standard protocol. Histology was taken as the gold standard of diagnosis. 
The dependent variable was histologically confirmed vulvar intraepithelial neoplasia. Logistic regression 
analysis to assess association of factors including age, age at sexual debut, multiple sexual partners, education, 
genital warts, menarche, alcohol, duration since diagnosisof HIV, and HPV infection with VIN was done. 
Results were presented in charts, graphs and tables. 
P-value less than 0.05was considered statistically significant. 
 
3. Results 
3.1 Characteristics of the study population 
The characteristics for the 225 participants in the study are described in Table 1. Most (211) of the study 
participants with the median age 37 (IQR 32-44) years didn’t have VIN compared to the 14 with a median age 
33 (IQR 32-36) years. Most (57.35%) of the participants without VINwere peasants who resided in the rural 
parts of Mbarara district with a monthly income of less than 50,000 Uganda shillings. All the participants were 
on ART. Of the participants without VIN 63 (29.86%), 62(29.38%) and 86 (40.76%) of the women had latest 
CD4 count ≤250, 251-349 and ≥350 cells/mm3 respectively. None of the participants with VIN had a recent CD4 
count of≤ 250cells/mm3 whereas the majority (78.57%) had a CD4 count ≥ 350 cells/mm3.  The prevalence of 
vulva intraepithelial neoplasiaamong HIV positive women attending HIVcare clinic at MRRH was determined 
by the formula: Prevalence= (n/Nx100). Where n, represents the total number of HIV positive women with VIN 
(14) attending the ISS clinic at MRRH and N, the total number of women enrolled (225). So the prevalence of 
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VIN among HIV positive women attending the HIVcare clinic at MRRH = (14/225 x 100) = 6.22% (95% CI 
3.44-10.22). 5 (2.22%) of the women had high grade intraepithelial neoplasia (VIN-2+) among which VIN-2 
were 4 (1.78%) and only one (0.44%) had VIN-3. 9 (4%) of the women had low grade vulva intraepithelial 
neoplasia (VIN-1). 
Table 1 Baseline characteristics 
Variable        VIN 
absent 
N=211 (%) 
VIN 
present 
N=14 (%) 
 Variable VIN 
absent 
N=211 (%) 
VIN 
present 
N=14 (%) 
 
Age,    median (IQR) 
 
37 (32-44) 
 
33 (32-36) 
 HPV infection 
Present 
Absent 
 
47 (22.27) 
164 (77.3) 
 
14 (100) 
Residence 
                    Rural 
                    Urban 
 
121 (57.35) 
  90 (42.65) 
 
9 (64.29) 
5 (35.71) 
 
 
On ART 
 
 
211 (100) 
 
14 (100) 
District 
      Mbarara 
      Isingiro 
      Kiruhura 
      Others 
 
93 (44.08)  
45 (21.33) 
 47 (22.27)  
26 (12.32) 
 
9 (64.29)  
3 (14.29)  
2 (21.43) 
- 
 Duration since HIV diagnosis 
(years)  
≤ 5 
≥6 
 
 
 
105 (49.76) 
106 (50.24) 
 
 
 
8 (57.14) 
6 (42.86) 
Marital status 
             Single  
             Monogamous  
             Polygamous                 
             Divorced                
             Widowed                
 
 
36 (17.06)    
41 (19.43)   
 49 (23.22) 
 43 (20.38) 
42 (19.91) 
 
1 (7.14) 
 2 (14.29)  
5 (35.71)  
5 (35.71) 
 1 (7.14)  
 
 
 
 H/o cervical screening result 
Positive                                      
Negative 
Not done 
 
 
5 (2.37) 
 66 (31.28) 
 140(63.35) 
 
 
1 (7.14) 
3 (21.43) 
10(71.43) 
Religion 
              Protestant 
              Catholic 
              Moslem 
              Others 
 
105 (49.76) 
 64 (30.33) 
        22 
(10.43) 
        20 
(09.48) 
 
9 (64.29) 
 4 (28.57) 
 - 
1 (7.14) 
 Recent CD4 count 
 
<250             
 251-349               
>350 
 
 
63 (29.86) 
62 (29.38) 
86 (40.76) 
 
 
- 
3 (21.43) 
11 (78.57) 
Substance use 
         Alcohol     
         Smoking      
Both alcohol and 
smoking 
 
 
8 (3.79) 
2 (0.95) 
- 
 
2 (14.29)  
         1 
(7.14) 
               - 
 WHO HIV clinical stage           
1 
                     2 
                     3 
                     4 
128 (60.66) 
  83 (39.34) 
- 
- 
 
 
14 (100) 
No. of sexual partners  
        Median (IQR)          
                  ≤ 1  
                  ≥ 2 
 
 
89 (42.18) 
122 (57.82) 
 
 
3 (21.43) 
11 (78.57) 
 Genital warts 
 
Present                                       
Absent 
 
 
88 (41.71) 
123(58.29) 
 
 
4 (28.57) 
10 (71.43) 
Education 
              None 
              Primary 
              Secondary 
              Tertiary 
 
 50 (23.70) 
 65 (30.80) 
53 (25.12) 
43 (20.38) 
 
2 (14.29) 
 8 (57.14) 
3 (21.43) 
1 (7.14) 
 
 
Age at menarche(years) 
Median (IQR) 
 
 
 
 
15 (14 –16) 
 
 
 
 
15 (14 – 6) 
Occupation 
               Business               
               Peasant               
               Employed                    
 
 
68 (32.23) 
77 (36.50) 
66 (31.28) 
 
 
6 (42.86) 
 5 (35.71)  
3 (21.43) 
 
 
 Age of first sexual intercourse 
(years) 
≤19 
≥ 20 
 
 
96 (45.50) 
 115(54.50) 
 
 
2 (14.29)  
12 (85.71) 
Monthly earnings 
(Ush) 
< 50,000/=             
50,000 - 100,000/= 
101,000-200,000/=           
> 200,000/= 
 
65 (30.81) 
 59 (27.96) 
 45 (21.33) 
 42 (19.91) 
 
4 (20.57)  
7 (50.00)  
2 (14.29) 
 1 (7.14) 
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The characteristics of the 14 participants identified with VIN as described in Table 1.The median age of the 
study participants with VIN was 33 (IQR: 32 – 36) years. All the 14 women with VIN were found to have 
human papilloma virus (HPV) infection. Only one (7.14%) with VIN smoked tobacco and another (7.14%) had a 
positive cervical cancer screening result. Of all (14) the study participants with VIN in this study, 6 (43%) 
presented with vulvar itching, 4 (29%) vulvar burning sensation, 2 (14%) dyspareunia and 2 (14%) were 
asymptomatic (figure 2). The following factors were analysed using multivariate model: age-group: <30, OR 
2.55 (95%CI0.28 - 23.17), p-value 0.29; age group 31-39 years OR 4.71 (0.84 – 26.52) p-value, 0.08; multiple 
sexual partner ≥ 2 OR 0.61 (0.12 – 3.16) p-value 0.56; age at sexual debut≤ 18 OR2.76 (0.48 – 15.74) p-value 
0.25; and genital warts OR 1.64 (0.31 – 8.68) p-value 0.56. 
 
Table 2A Univariate analysis of factors associated with VIN  
Characteristic Univariate  Model 
Unadjusted OR (95%CI)    P-values 
Age group in years 
<30 
31-40 
≥40 
 
4.75(0.90-5.04) 
2.38(0.34-16.36) 
1.00 
 
0.07 
0.38 
 
Multiple sexual partners 
                      ≤ 1 
                      ≥ 2 
 
1.00 
0.72 (0.16 - 3.17) 
0.17 
 
Age of sexual debut 
≤ 18 
≥ 19 
 
2.65 (0.530 – 13.32) 
1.00 
0.13 
 
 
Menarche 
≤ 13 
≥ 14 
 
1.00 
2.17 (0.244 - 19.276) 
0.49 
Duration since HIV diagnosis  
≥6 years 
≤5 years 
 
1.00 
1.72 (0.23 – 2.38) 
0.59 
 
Genital warts    
No 
Yes  
 
1.00 
2.40 (0. 9 -9.82) 
0.22 
 
Residence  
Urban  
Rural 
 
1.00 
0.89 (0.27 - 2.90) 
0.84 
Alcohol 
No 
Yes 
 
1.00 
1.19 (0.213 - 6.694) 
0.84 
Education  
None  
Primary or higher 
 
1.00 
0.99 (0.48 - 2.03) 
0.97 
 
In the univariate analysis, no factors were significantly associated with VIN. Variables with p-values < 0.40 
were transferred and analysed using multivariate model to check for significance.  
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Table 2B Multivariate analysis of factors associated with VIN 
Characteristic                     Multivariate  Model 
Unadjusted OR (95%CI) P-values 
Age group in years 
<30 
31-40 
≥40 
 
2.55 ( 0.28 - 23.17) 
4.71 (0.84 – 26.52) 
1.00 
 
0.29 
0.08 
 
Multiple sexual partners 
≤ 1 
≥ 2 
 
1.00 
0.61 (0.12 – 3.16) 
0.56 
 
Age of sexual debut 
≤ 18 
≥ 19 
 
2.76 (0.48 – 15.74) 
1.00 
0.25 
 
 
Menarche 
≤ 13 
≥ 14 
 
1.00 
3.8 0 (0.42 - 35.79) 
0.23 
Genital warts    
No 
Yes  
 
1.00 
1.64 (0.31 – 8.68) 
0.56 
 
 
No factors were found to be significantly associated with VIN. 
 
Figure 1 Distribution of VIN by grade. 
  
 
Vulva intraepithelial neoplasia grade 1 (VIN-1) which has a low potential for development of vulvar cancer was 
the commonest (4%); followed by VIN-2 (1.78%) and VIN-3 (0.44%). 
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Fig.2 Distribution of the clinical presentation with VIN 
 
 
Fig 3 Clinical findings in participants with VIN.  
 
Among patients with VIN, 8 (57.14%) had normal vulva, 5 (35.71%) had genital warts, and only one (7.15%) 
had vulva pigmentation. 
 
4. Discussion 
4.1 Prevalence of vulva intraepithelial neoplasia (VIN) 
Limited data are available on the prevalence of vulva intraepithelial neoplasia (VIN) in HIV-positive women 
therefore there are only a few studies for comparison. In this study, the prevalence of vulva intraepithelial 
neoplasia among HIV-positive women attending ISS clinic at MRRH was found to be 6.22% (95% CI 3.44-
10.22). Byrne and colleagues (1989) found the prevalence of VIN to be 16% among eighteen HIV-positive 
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women in St. Mary’s Hospital, London. The difference with that in this study could be due to the different 
settings and patients profiles. Also, the sample size in our study was larger than that used by Bryne.  
The prevalence of vulva intraepithelial neoplasia (VIN) in this study was also lower than that of a study done by 
Korn AP et al (1998) where they found the prevalence of VIN to vary from 9% to 37%. This was a compilation 
of prevalence of VIN from different colposcopy clinics in Africa. They only included mothers with abnormal 
results of cytological examination who were referred for colposcopy thus they may have had selection bias. Our 
study took into consideration all women who were HIV positive without subjecting them to cytological 
examination which would have otherwise left out those with VIN in this population. 
In a study carried out by Olamide Dosekun and colleagues (2013) among HIV-positive women attending the 
vulval dermatology clinic at St. John’s Institute of Dermatology, St. Thomas’ Hospital, London from January 
2007 to August 2012, the prevalence of vulva intraepithelial neoplasia was found to be 57% out of 14 HIV-
positive women identified. This is much higher than the prevalence of VIN in this study. Our sample size was 16 
times higher than that used by Olamide Dosekun et al., 2013.  
In another study conducted among 343 patients referred with an abnormal genital intraepithelial lesion or 
cytology to the University of Tennessee, West Clinic gynecology oncology division between June 2006 and 
December 2009 (Wendy Likes et al.,2013), the prevalence of VIN among immuno-compromised patients was 
found to be 76% (N=33). This is much higher than that in this study and could be explained by the following: 
Firstly, Likes and colleagues determined VIN in all immuno-compromised patients whereas our study was 
specific to only HIV-positive women. Secondly, these immuno-compromised patients already had abnormal 
genital lesions and cytology with high possibility of being VIN. 
4.2 Clinical features of vulva intraepithelial neoplasia 
The symptoms of vulva intraepithelial neoplasia in this study included vulvar itching, vulvar burning sensation 
and dyspareunia. These symptoms are not unique to VIN and often under looked. Patients may therefore present 
late with VIN or vulvar cancer. However, no studies were available to compare with the above. 
4.3 Factors associated with vulva intraepithelial neoplasia (VIN) 
The factors associated with vulva intraepithelial neoplasia (VIN) in various studies include HPV infection 
(Conley LJ et al., 2002,Massad LS et al., 2004, De Vuyst H et al., 2009), smoking (Dahling JR et al., 1992; 
Brinton LA et al., 1990; Massad LS et al., 2012), history of abnormal papanicolaou test (Massad LS et al., 2004 
and Brinton et al., 1990), multiple sexual partners, young age at first sexual intercourse (Ho L et al., 1993, Kiviat 
NB et al., 1989, and Brinton et al., 1990 ), and genital warts (Brinton LA et al., 1990). 
In this study, 14 (100%) participants with VIN were found to have human papilloma virus (HPV) infection. This 
is in agreement with the following studies which found out that HPV was significantly associated with VIN 
(Conley LJ et al., 2002, Massad LS et al., 2004, and  De Vuyst H et al., 2009). Human papilloma virus (HPV) 
infection in this study was determined by histology rather than Polymerase Chain Reaction (PCR).  
Various studies have shown that the age of the women developing vulva intraepithelial neoplasia, which was 
historically judged to be postmenopausal, had decreased during several decades (Sturgeon SR et al., 1992; 
Kaufman RH et al 1995; Jones RW et al., 1997; De Vuyst H et al., 2009; Dutta et al., 2012). Conley LJ and 
colleagues (2002) found the median age of HIV-positive women who developed vulva intraepithelial neoplasia 
in a prospective cohort study done in USA to be 38 years (IQR 33–40). In this study, the median age of HIV-
positive women with VIN was 33 years (IQR 32-36) which is lower than that found by Conley and colleagues 
(2002).  
Although smoking tobacco was found to be highly associated with vulva intraepithelial neoplasia in various 
studies (Dahling JR et al., 1992; Brinton LA et al., 1990; Massad LS et al., 2012), only one of the 14 participants 
with VIN in this study smoked tobacco. 
Age at first sexual intercourse and having multiple sexual partners were not significantly associated with VIN in 
this study. This is contrary to the findings of Ho L et al., (1993), Kiviat NB et al., (1989) and Brinton et al., 
1990. This variance might be that the women did not tell the truth.  Genital warts were not also significantly 
associated with VIN in this study. However, Brinton LA and colleagues (1990) found that genital warts were 
strongly associated with VIN. 
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In this study only one of the participants with VIN had history of previous abnormal cervical cancer screening 
result and thus couldn’t determine its association with VIN. However, studies by Massad LS et al., 2004 and 
Brinton et al., 1990 found out that history of abnormal papanicolaou test was highly associated with VIN. 
4.4 Limitations 
Due to the lower prevalence and limited time we were not able to get enough sample size for determination of 
the factors associated with VIN among HIV positive women at MRRH. 
4.5 Conclusion 
The prevalence of VIN among HIV-positive women attending HIV care clinic at MRRH was low. All 
participants with VIN had HPV infection; common symptoms included vulva itching, vulva burning sensation 
and superficial dyspareunia. Majority of women with VIN had no physical findings therefore were only 
identified on vulvoscopy. 
Since all cases of VIN had HPV infection we recommend that HPV vaccination should be included in HIV care 
to prevent VIN and consequently vulva cancer. We also recommend that all women with vulva itching, vulva 
burning and superficial dyspareunia should be screened for VIN. Vulvoscopy should be included in reproductive 
healthcare since majority present with no symptoms. Finally we recommend a big study to determine the factors 
associated with VIN.  
 
References 
Brinton LA, Nasca PC, Mallin K, et al: Case-control study of cancer of the vulva. ObstetGynecol 75:859, 1990. 
Byrne MA, Taylor-Robinson D, Munday PE, Harris JR. (1989) The common occurrence of human 
papillomavirus infection and intraepithelial neoplasia in women infected by HIV. AIDS 3:279 
Chiasson MA, Ellerbrock TV, Bush T et al. (1997). Increased prevalence of vulvovaginalcondyloma and vulvar 
intraepithelial neoplasia in women infected with the human immunodeficiency virus. ObstetGynecol; 
89:690. 
Conley LJ, Ellerbrock TV, Brush TJ et al. (2002). HIV-1 infection and risk of vulvovaginal and perianal 
condylomataacuminata and intraepithelial neoplasia: A prospective cohort study. Lancet 359:108.  
De Vuyst H, Clifford GM, Nascimento MC, et al. (2009). Prevalence and type distribution of human 
papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-
analysis. Int J Cancer; 124:1626–36. 
DuttaD.C. Text book of Gynaecology 6th edition (2012). Vulva intraepithelial neoplasia Chapter 22 page 304. 
Ferenczy A, Coutlee F, Franco E, Hankins C (2003). Human papillomavirus and HIV coinfection and the risk of 
neoplasias of the lower genital tract: a review of recent developments. CMAJ [Review] 169(5):431–
434. 
Hart WR. (2001). Vulvar intraepithelial neoplasia: historical aspects and current status.Gynecol Path. 20(1):16-
30.  
Ho L, Tay SK, Chan SY, Bernard HU: (1993). Sequences of variants of HPV type 16 from couples suggest 
sexual transmission with low infectivity and polyclonality in genital neoplasms. J Infect Dis 168:803.  
Jones RW, BaranyaiJ,Stables S: (1997). Trends in squamous cell carcinoma of the vulva: The influence of vulvar 
intraepithelialneoplasia.ObstetGynecol 90:448. 
Jones RW, Rowan DM, Stewart AW (2005). Vulvar intraepithelial neoplasia: aspects of the natural history and 
outcome in 405 women. Obstet Gynecol. 106 (6):1319–1326.  
Joura EA, Losch A, Haider-Angeler MG, et al. (2000). Trends in vulvar neoplasia. Increasing incidence of 
vulvar intraepithelial neoplasia and squamous cell carcinoma of the vulva in young women.J Reprod 
Med; 45:613–15. 
Judson PL, Habermann EB, Baxter NN, et al. (2006). Trends in the incidence of invasive and in situ vulvar 
carcinoma.Obstet Gynecol. 107(5):1018–1022.  
Kiviat NB, Koutsky LA, Paavonen JA, et al: (1989). Prevalence of genital papilloma virus infection among 
women attending a college student health clinic or a STD clinic. J Infect Dis 159:293.  
Klapper, A, DelPriore, G, et al: (2011). Vulvar Intraepithelial NeoplasmsGlob. libr. women's med.,(ISSN: 1756-
2228); DOI 10.3843/GLOWM.10258 
Journal of Health, Medicine and Nursing                                                                                                                                          www.iiste.org 
ISSN 2422-8419     An International Peer-reviewed Journal 
Vol.27, 2016 
 
106 
Korn AP, Abercrombie PD, Foster A. (1998). Vulvar intraepithelial neoplasia in women infected with human 
immunodeficiency virus in Africa. Cancer; 82: 2401-8. 
Koutsky L. (1997). Epidemiology of genital human papillomavirus infection. Am J Med. 102:3–8.  
Maiman M, Fruchter RG, Clark M, et al. (1997). Cervical cancer as an AIDS-defining illness.ObstetGynecol; 
89:76. 
Maiman M, Fruchter RG, Serur E, Remy JC, Feuer G, Boyce J. (1990). Human immunodeficiency virus 
infection and cervical neoplasia.Gynecologic Oncology. 38(3):377–382.  
Massad LS, Silverberg MJ, Springer G. et al. (2004). Effect of antiretroviral therapy on theincidence of genital 
warts and vulvar neoplasia among women with the human immunodeficiency virus. Am J Obstet 
Gynecol. 2004 May; 190(5):1241-8. 
Massad LS, XianhongXie, Teresa Darragh et al.(2011).Genital Warts and Vulvar Intraepithelial Neoplasia: 
Natural History and Effects of Treatment and Human Immunodeficiency Virus Infection.Obstet 
Gynecol. 118(4): 831–839.  
OlamideDosekun, PippaFarrugia, Fiona Lewis and GulshanSethi.  (2013). Vulval disease in HIV-positive 
women attending a tertiary vulval dermatology clinic over a five-year period.International Journal of 
STD & AIDS; 24(10) 834–836. 
Robinson WR, Barnes SE, Adams S, Perrin MS. (1997). Histology/cytology discrepancies in HIV-infected 
obstetric patients with normal pap smears.GynecolOncol. 65:430. 
Spitzer M. (1999). Lower genital tract intraepithelial neoplasia in HIV-infected women: guidelines for evaluation 
and management.ObstetGynecolSurv. 54:131. 
Skapa P, Zamecnik J, Hamsikova E, et al. (2007). Human papillomavirus (HPV) profiles of vulvar lesions: 
possible implications for the classification of vulvar squamous cell carcinoma precursors and for the 
efficacy of prophylactic HPV vaccination. Am J SurgPathol. 31:1834–1843. 
van der Avoort IAM, Shirango H, Hoevenaars BM, et al. (2006). Vulvar a multifactorial disease following two 
separate and independent pathways. International Journal of Gynecological Pathology. 25(1):22–29. 
vanSeters M, van Beurden M, de Craen AJ. (2005). Is the assumed natural history of vulvar intraepithelial 
neoplasia III based on enough evidence? A systematic review of 3322 published 
patients.GynecolOncol. 97(2):645–651 
Wendy Likes, Joseph T. Santoso, Jim Wan Arch. (2013). A cross-sectional analysis of lower genital tract 
intraepithelial neoplasia in immune-compromised women with an abnormal Pap.GynecolObstet 
287:743–747 DOI 10.1007/s00404-012-2637-3 
 
Competing interests 
Authors did not have any conflict of interest 
 
Authors' contributions:  
1. Andrew Oryono.MD, Principal investigator, conceived the idea, developed the concept, involved in 
data collection, entry, analysis and manuscript writing 
2.  Mayanja Ronald.MD, involved in data collection, entry, analysis and manuscript writing 
3.  Ngonzi Joseph.MD, involved in development the concept, data management and manuscript writing  
4. Prof. YarineFajardo.pHD, involved in development the concept, data management and manuscript 
writing  
5. Dr. Wasswa Ssalongo, Senior Consultant(obs/gyn), involved in development the concept, data 
management and manuscript writing  
 
 
Authors' information:  
1. Andrew oryono, MBChB(Gulu University), Senior resident (Mbarara University of Science and 
Technology 
2. Mayanja Ronald, MBChB(MUST), MMed O&G(MU), Lecturer, Department of obstetrics and 
Gynaecology, Mbarara University of Science and Technology,  Uganda 
3. Ngonzi Joseph, MBChB(MUST), MMed O&G(MUST), PhD candidate, Senior lecturer, Chair 
Department of obstetrics and Gynaecology, Mbarara University of Science and Technology,  Uganda 
4. Prof. YarineFajardo.PhD 
5. Dr. Wasswa Ssalongo, Senior Consultant(obs/gyn) 
 
Journal of Health, Medicine and Nursing                                                                                                                                          www.iiste.org 
ISSN 2422-8419     An International Peer-reviewed Journal 
Vol.27, 2016 
 
107 
Acknowledgements 
My lecturers; Prof. Yarine Fajardo, Dr. Kayondo Musa, Dr. Wasswa Ssalongo, Dr. Godfrey Mugyenyi, Dr. Julius 
Mugisha, others Dr Samson Okello , Dr Francis Bajunirwe for the statistical input and Prof. Damaris Latiffa for the 
histopathological work. I am indebted to my research assistants Sr Alexcer Namuli, Sr Alice Najjuma and Sr Susan 
Asiimwe. Lastly all the study participants, staff of ISS/CCP clinics. I acknowledge my classmates Abdul 
Namugongo, Ayol Mac Ayol, Damulira Adam, Inzama Wilfred, Muhumuza Joy, and Nanzira Rachael Samantha.
Finally my regards go to my sponsor ONCOLOGY FOR AFRICA for the financial support. 
 
 
 
 
 
